Catherine Oakman

Identification of a serum-detectable metabolomic fingerprint potentially correlated with the presence of micrometastatic disease in early breast cancer patients at varying risks of disease relapse by traditional prognostic methods

Catherine Oakman, Leonardo Tenori, Wederson M. Claudino et al. · Annals of Oncology · 2011 · 99 citations · Full text

Life Sciences, Biochemistry, Oncology +16

Serum metabolomic profiles evaluated after surgery may identify patients with oestrogen receptor negative early breast cancer at increased risk of disease recurrence. Results from a retrospective study

Leonardo Tenori, Catherine Oakman, Patrick G. Morris et al. · Molecular Oncology · 2014 · 96 citations · Full text

Medicine, Biochemistry, Oncology +17

Exploration of serum metabolomic profiles and outcomes in women with metastatic breast cancer: A pilot study

Leonardo Tenori, Catherine Oakman, Wederson M. Claudino et al. · Molecular Oncology · 2012 · 92 citations · Full text

Life Sciences, Biochemistry, Oncology +16

Giredestrant for Estrogen Receptor–Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study

Miguel Martín, Elgene Lim, Mariana Chávez‐MacGregor et al. · Journal of Clinical Oncology · 2024 · 63 citations · Full text

Medicine, Oncology, Pharmacology +17

Prognostic and predictive value of TP53mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial

Lynnette Fernandez‐Cuesta, Catherine Oakman, Priscila Falagan-Lotsch et al. · Breast Cancer Research · 2012 · 57 citations · Full text

Medicine, Molecular Medicine, Oncology +17